Nextcure presents initial data from clinical trial of nc762 and a trial in progress poster for nc410 combo at the 2022 society for immunotherapy of cancer annual meeting

Beltsville, md., nov. 07, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator emese zsiros, m.d., ph.d., associate professor of oncology, chair, department of gynecologic oncology, roswell park comprehensive cancer center, will present initial clinical data from a phase 1 clinical trial of nc762 and eric christenson, m.d., department of medical oncology, sidney kimmel comprehensive cancer center, johns hopkins university school of medicine, will present a trials in progress poster for a combo study of nc410 at the society for immunotherapy of cancer (sitc) annual meeting in boston. the initial clinical data come from a phase 1 study evaluating nc762, a monoclonal antibody that binds specifically to b7-h4, in patients with advanced/metastatic solid tumors.
NXTC Ratings Summary
NXTC Quant Ranking